The Enrolled Asset: How the CMS Moratorium Is Reshaping Home-Based Care Deal Structuring Into 2027

Short answer: The CMS enrollment moratorium is not just a pause on new agencies. It is a repricing event for every enrolled home health and hospice provider, because it also blocks certain majority-ownership changes that require re-enrollment. That makes a clean Medicare provider number scarce and, in some structures, harder to transfer. The result: through the H2 2026 to Q1 2027 window, deal structure rather than price alone decides which transactions get done. Joint ventures and minority stakes are rising, buyers must re-underwrite enrollment risk, and sellers with clean, transferable enrollment hold real leverage.

On May 13, 2026, CMS imposed a six-month nationwide moratorium on new Medicare enrollments for home health agencies and hospices. As of this writing, we are roughly halfway through it. The scheduled end is mid-November 2026, but that date is a default, not a promise. CMS can extend it in six-month increments, and it can lift it early. Neither is guaranteed, and the market is being forced to underwrite both possibilities at once.

Most of the coverage so far has treated this as a startup story: you cannot stand up a new agency and bill Medicare until the freeze lifts. That is true, and it matters. But it undersells what is actually happening. The moratorium is a repricing event for every enrolled home health and hospice provider in the country (we covered why it reprices the market here), and it changes how deals in this sector should be structured for at least the next several months.

By the numbers: the moratorium-era deal environment

The freeze landed on an active, deadline-driven market, not a dormant one. A few current figures frame why structure now matters more than it did six months ago.

Regulatory clock and rate backdrop

• May 13, 2026. Effective date of the six-month nationwide moratorium on new Medicare enrollments for home health agencies and hospices, with a default expiration around mid-November 2026 that CMS can extend in six-month increments or lift early (CMS Federal Register, 2026).
• Net +2.4%. The proposed CY 2027 home health payment change, roughly $420 million, a sharp reversal from the CY 2026 final rule’s 1.3% cut. The rule is proposed, not final, with comment open through late August 2026 (CMS CY 2027 HH PPS proposed rule, July 1, 2026).
• 36 months. The lookback window in which a non-exempt change in majority ownership can trigger a new Medicare enrollment requirement, the exact requirement the moratorium now denies (42 CFR 424; CMS change-of-ownership guidance).

Deal activity through H2 2026

• 55 transactions. Home health and hospice deals through the first six months of 2026, a slightly slower pace than the 58 in the same period of 2025, with hospice leading sub-sectors (Levin Associates; Mertz Taggart Q1 2026).
• ~41%. Share of first-half 2026 home health and hospice transactions committed by private equity, alongside high-profile platform deals (Levin Associates, 2026).
• $3B and $1.1B. The year’s marquee platform deals, General Atlantic’s acquisition of TEAM Services Group and Kinderhook’s take-private of Enhabit, evidence that conviction capital is still deploying at scale (Levin Associates, 2026).

Enforcement direction

• Retroactive revocations. The CY 2027 proposed rule would make all Medicare enrollment revocation grounds retroactive, expand denial and revocation authorities, and ratchet up penalties tied to majority-ownership-change violations (CMS CY 2027 HH PPS proposed rule; Holland & Knight, 2026).
• PE and REIT disclosure. The same rule proposes expanded ownership-disclosure requirements reaching private equity and REIT investors, a signal that ownership changes are under heightened federal scrutiny (CMS; Holland & Knight, 2026).

What is the goal of this article?

This piece explains what the moratorium changes for anyone weighing a home health or hospice transaction between now and Q1 2027, and how to structure around the one constraint that most operators are still underweighting: the re-enrollment trigger.

Most conversations about the moratorium stop at the headline, no new agencies until it lifts. The more consequential question for operators and investors is what it does to the value and transferability of enrolled providers, and how deals should be structured while the freeze is live. That is where the real decisions sit, and it is what we work through below.

Key takeaways

• The freeze reaches ownership changes, not just startups. A non-exempt change in majority ownership within the 36-month window can trigger a re-enrollment the moratorium now denies. The enrollment, not the entity, is the asset.
• Scarcity is now priced into the enrolled CCN. When new supply cannot be created, a clean Medicare provider number appreciates, and buyers must price the confidence that the enrollment survives the transaction.
• Joint ventures and minority structures are having a moment. They let capital reach enrolled providers without forcing an immediate majority-ownership change that the moratorium would block.
• The market is active, not frozen. Fund-return pressure and strategic demand are driving deal volume into a constrained supply of enrolled providers, the exact condition where structure decides outcomes.
• Q1 2027 sets up as a release point. A friendlier proposed rate backdrop and a tighter enforcement regime could arrive together as the freeze lifts, rewarding operators who prepared during the pause.
• Preparation is the differentiator. Sellers with clean, transferable enrollment run faster processes; buyers who model compliant structures win assets others cannot touch.

Why does the moratorium reprice enrolled providers, not just block startups?

Because it reaches certain changes in majority ownership that would require the acquired entity to re-enroll, and re-enrollment is exactly what the freeze denies. Under CMS rules, a non-exempt change in majority ownership within the applicable 36-month window can trigger a new enrollment requirement.

Translated into deal terms: a straightforward acquisition of a controlling interest in an enrolled agency may not simply transfer the asset you think you are buying. If the structure trips the re-enrollment trigger, the very Medicare billing privileges that give the target its value can be frozen on the other side of the closing table. The enrollment, not the entity, is the asset. And right now that asset is not freely transferable in every structure.

This is the difference between a deal that closes clean and a deal that closes into a billing gap. It is not a footnote for counsel to sort out post-signing. It is a first-order question that determines whether the transaction is worth doing at all.

How does scarcity change what an enrolled CCN is worth?

When you cannot create new supply, existing supply appreciates. A clean, enrolled Medicare provider number is now a genuinely scarce asset, because the ordinary path to creating a new one is closed. For sellers holding well-run agencies with defensible compliance histories, this is leverage. For buyers, it means the underwriting has to change.

The premium is no longer just for census, referral relationships, and margin. It is for the enrollment itself, and specifically for the confidence that the enrollment survives the transaction. That confidence has to be diligenced explicitly. Buyers who continue to price these assets the way they did in April are either overpaying for enrollment risk they have not quantified or walking away from deals they could have structured around. For the fuller picture of what actually drives buyer conviction and valuation, enrollment integrity now sits alongside the referral, census, and margin factors buyers already scrutinize.

Why are joint ventures and minority structures gaining ground?

Because if a controlling-interest acquisition risks tripping the re-enrollment trigger, the rational move is to reach the same economic outcome through a structure that does not. That is why joint ventures, management arrangements, and minority-stake investments are drawing more interest right now than clean buyouts.

The logic is straightforward. A minority investment or a well-constructed JV can let a growth-minded operator gain economic exposure, operational influence, and a defined path to future control without forcing an immediate change in majority ownership that the moratorium would block. The recent large minority divestitures in this sector are a signal of the same underlying pressure: capital is finding its way into enrolled providers through structures that preserve the enrollment.

None of this is a workaround in the pejorative sense. It is disciplined structuring in response to a real constraint. Done well, it protects both sides. Done carelessly, it creates a JV that looks like a change of control to a MAC and produces exactly the outcome it was meant to avoid.

What does the H2 2026 deal market actually look like?

It is an active market transacting into a constraint, not a frozen one working around a freeze. The moratorium landed on a market already leaning into dealmaking, which is precisely why its structural effects matter so much.

The through-line across the sell-side advisory community is that deal volume is building, not receding. Home-based care M&A held steady in Q1 2026 at 22 closed transactions, with hospice leading all sub-sectors, and Q2 stepped up materially from there. Private equity accounted for roughly 41% of home health and hospice transactions in the first half of the year. Through the first six months of 2026, the sector logged 55 home health and hospice deals, essentially on pace with the 58 in the same period of 2025.

What is driving it is not sentiment. It is fund math. A meaningful number of sponsor platforms have now been held five, six, or seven years, and the pressure to return capital to LPs is real and time-bound. Those funds need to transact, moratorium or not. On the other side, strategics are pursuing local density and referral adjacency, and the largest platform deals of the year, General Atlantic’s roughly $3 billion acquisition of TEAM Services Group and Kinderhook’s $1.1 billion take-private of Enhabit, confirm that conviction capital is still being deployed at scale.

Put those two facts together and the picture is specific: strong, deadline-driven demand meeting a supply of enrolled providers that the moratorium has made harder to create and, in certain structures, harder to transfer. That is the exact condition under which structure, rather than price alone, decides which deals get done.

What is the Q1 2027 outlook: rate backdrop and enforcement?

A better proposed reimbursement backdrop and a sharper enforcement edge, potentially arriving together. The forward view improves the case for acting deliberately now rather than waiting.

On reimbursement, the direction of travel has reversed. On July 1, 2026, CMS proposed a net 2.4% increase in aggregate home health payments for CY 2027, about $420 million, driven by a 2.1% payment update plus an outlier adjustment. That stands in sharp contrast to the CY 2026 final rule, which cut payments by 1.3%. Notably, for the first time since CY 2022, CMS did not apply a new permanent PDGM behavioral adjustment, though it did propose continuing a temporary 3.0% reduction. The rule is proposed, not final, and the comment period runs through late August 2026, so nothing is locked. But the signal to buyers underwriting 2027 cash flows is a friendlier rate environment than the sector has seen in several years, and that tends to support valuations rather than compress them.

On enforcement, the same rule sharpens the edge the moratorium started. CMS proposed making all enrollment revocation grounds retroactive, expanding denial and revocation authorities, and, most relevant here, ratcheting up penalties tied to majority-ownership-change violations. It also proposed expanded ownership-disclosure requirements reaching private equity and REIT investors. Read alongside the moratorium, the message is consistent and it is not softening: ownership changes in this sector are under heightened federal scrutiny, and the cost of getting a change-of-control structure wrong is rising, not falling.

So the Q1 2027 setup is a specific one. If the moratorium holds to its default timeline, it lifts in mid-November 2026, roughly at the turn into the new payment year and the new-year deal cycle. That would release built-up demand into a market with a better rate backdrop and a tighter enforcement regime at the same moment. The operators who prepared during the pause, cleaning up enrollment and modeling compliant structures, are the ones positioned to move in that first-quarter window. The ones who waited will be assembling their story while the prepared are already at the table.

The counter-scenario deserves equal weight. CMS can extend the moratorium in six-month increments, which would push the workaround structures, JV, minority, and staged control, from a bridge into the primary tool for most of 2027. Either way, the structural discipline the moratorium demands is not a temporary inconvenience to wait out. It is the operating condition for dealmaking in this sector for the foreseeable planning horizon.

What does this mean through the Operate, Optimize, Exit lens?

The moratorium touches each phase of a home-based care lifecycle differently. Where you sit in that lifecycle determines what the freeze asks of you.

Operate

Currently enrolled providers can continue to participate without interruption. If anything, the freeze raises the strategic value of the enrollment you already hold. This is the moment to treat compliance posture and clean enrollment documentation as balance-sheet assets, because in a transaction they now are.

Optimize

Organic growth, census expansion, and workforce depth are the levers still fully available to you. With the fastest inorganic path constrained, the operators who use this window to tighten operations and improve quality are the ones who will command the strongest multiples when consolidation resumes.

Exit

For sellers, scarcity is on your side, but only if the asset is genuinely clean. A buyer is now pricing enrollment survivability directly, which means quality of earnings, ownership history, and enrollment integrity get scrutinized harder than before. Sellers who prepare for that scrutiny in advance will run faster, cleaner processes. Sellers who do not will watch value leak out during diligence.

The practical takeaways

For sellers

Your enrolled Medicare provider number is more valuable today than it was in the spring, but that value is fragile. It depends on a clean ownership history and a compliance record that survives a buyer’s diligence. Prepare the enrollment story before you go to market, not during it. Our Seller Readiness Playbook lays out the twelve-to-twenty-four-month readiness work, across valuation, EBITDA and KPI visibility, owner-dependency risk, and deal structure, that turns a clean asset into a clean process.

For buyers

Re-underwrite. Price enrollment portability and re-enrollment risk explicitly. Model the structures, JV, minority, and staged control, that let you reach your economic goal without triggering a re-enrollment the moratorium would block. The buyers who structure thoughtfully right now will win assets that less prepared competitors cannot touch.

For both

The clock is the variable nobody controls. The November date is a planning assumption, not a certainty, and the possibility of extension is real. Build that uncertainty into your structure and your timeline rather than betting on a single outcome.

The bottom line

The moratorium did not stop dealmaking in home-based care. It changed the shape of it. The question for any operator weighing a transaction over the next several months is not whether to act, but whether the structure protects the one asset the moratorium has made scarce.

Enrollment moratoria in this sector have historically ended, and when they do, the deals that were structured in the freeze tend to convert quickly into the transactions the market was waiting to do. The operators who prepared during the pause, cleaning up enrollment, tightening operations, and modeling structures in advance, are the ones positioned to move first when it lifts.

What a clean, well-prepared asset can achieve even in a demanding market is not theoretical. When Montauk served as placement agent on the sale of GrandCare Health Services to The Pennant Group (NASDAQ: PNTG), the seller was a five-star post-acute home health provider with a two-decade operating history and defensible fundamentals. The result was a public-market exit with no broad layoffs and high staff engagement after close. That is the profile buyers stretch for: a clean enrollment, a durable referral base, and a compliance record that holds up under scrutiny. In this environment, those qualities are worth more than they have been in years.

About Montauk AI

Montauk AI is a home-based care investment bank. We work with founder-led and mid-market operators across home health, hospice, home care, palliative, and post-acute care, across the full Operate, Optimize, Exit lifecycle.

In Operate, we build the FP&A foundation, KPI infrastructure, monthly close cadence, and board-ready reporting that defines a serious business. In Optimize, we engineer enterprise value through EBITDA uplift, workforce utilization, clinical quality improvements, payer optimization, and technology enablement. In Exit, we run the transaction through algorithmic buyer matching, CIM and comps strategy, and AI-accelerated execution. For our extended treatment of the architecture behind this work, see our AI-Native Investment Banking research paper, or get the Seller Readiness Playbook whitepaper.

Weighing a home health or hospice transaction before the freeze lifts?

The moratorium changes what your enrolled asset is worth and how a buyer can structure around it. If you operate in home health, hospice, home care, palliative, or post-acute care and want a straight read on how to structure a transaction in this environment, whether you are preparing to sell an enrolled asset or looking to acquire one without tripping the re-enrollment trigger, we would welcome the conversation. Reach Jarrett Bauer at jbauer@montauk.ai, or learn how we engage across Operate, Optimize, Exit at montaukai.com. Explore more on our blog.